A LinkedIn post from C Ray Therapeutics highlights growing industry focus on isotope purity and supply scalability in radiopharmaceuticals, particularly around Lutetium-177 and Actinium-225. The post contrasts carrier-added Lu-177, which can introduce long-lived impurities and regulatory complexity at scale, with no-carrier-added Lu-177, which it suggests is becoming the preferred standard as programs mature toward commercialization.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The post also points to the emerging importance of Actinium-225, referencing ITM Isotope Technologies Munich SE’s “Actineer” joint venture aimed at high-purity, large-scale production. This framing implies that secure, scalable access to Ac-225 may become a bottleneck or differentiator for future radiopharma pipelines.
For Asia-focused radiopharma programs, the post describes isotope purity and supply consistency as critical manufacturing challenges, emphasizing the need to stress-test supply chain assumptions early. This perspective suggests that companies able to lock in reliable radioisotope sourcing and infrastructure could gain a competitive and regulatory advantage as the sector moves from development to commercial production.
According to the post, C Ray Therapeutics is co-organizing the International RDC Sub-Forum at the XDC Conference 2026 in Chengdu, where ITM Pharma Solutions’ Dr. Hamid Hamzeiy is expected to speak on the shift “from isotope scarcity to scalability.” For investors, this involvement may indicate C Ray’s strategic engagement in regional ecosystem-building and supply chain discussions that could influence future partnership opportunities and positioning in Asian radiopharma markets.